Skip to main content
OpenTrials
Completed

NCT Number: NCT04703738

Evaluation of Geistlich Fibro-Gide® in Comparison to CTG for the Treatment Around Implants

This double blind, randomized, parallel study evaluates the non-inferiority of Geistlich Fibro-Gide® in comparison to connective tissue graft for soft tissue volume augmentation around dental implants

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Soft Tissue Defect

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Regenerative Solutions, Fullerton, California, United States

Loading trial locations.

About this study

A total sample size of 60 subjects (n=60) will be evaluated at 5 centers, by 6 Investigators with approximately 10-subjects per Investigator. Power analysis based on 80% power, past Thoma, Zeltner and González-Martin studies 1,2,3 and a one-sided confidence interval of 0.025, indicates that with a volume change standard deviation between 0.5 and 0.7 mm, 17-31 subjects are required per group (test and control), so 50-60 subjects are an acceptable estimate, with a preference for 60, given potential loss to long-term follow-up.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects requiring soft tissue augmentation around single implants, i.e., thin biotype with potential for
  • All implants must be at least 6 months post bone graft/implant placement
  • have at least 1 mm of keratinized tissue width (KTw),
  • have final restoration permanently in place for at least 4-weeks and
  • subject have no recession on the implant body
  • Subjects who, can achieve good oral hygiene (80% plaque free surfaces on the implant and maintain 80% plaque free surfaces on teeth adjacent to treatment sites).

Exclusion criteria

  • participation within the last six months in other interventional studies.
  • any systemic condition that could influence healing, such as uncontrolled diabetes mellitus - confirmed by A1C score ≥7% - cancer, HIV, oral muco- cutaneous conditions and drug induced gingival enlargement.
  • taking medications that compromise wound healing, such as chronic steroid use - either inhaler or systemic, calcium channel blockers with secondary hyperplastic tissue reactions, anti-seizure medications, IV bisphosphates for bone metabolic diseases, radiation or other immuno-suppressive therapy.
  • acute infectious lesions in the areas intended for surgery.
  • History within the last 6 months of weekly or more frequent use of nicotine products
  • Female subjects who are pregnant or lactating, or sexually active female subjects who are of childbearing potential and who are not using hormonal or barrier methods of birth control
  • Untreated, moderate to severe periodontal disease.

Treatment and study plan

Soft tissue flap + Connective Tissue Graft

Procedure

The treatment site is accessed using a full thickness flap extending at least 1 full tooth mesial and distal, vertical releasing incisions may be used to obtain flap release for full coverage of the treatment site and graft without compression. The harvest graft donor area will be the palate in the bicuspid region on the same side as the control soft tissue augmentation therapy. The CTG will be harvested using full thickness incisions that include the periosteum and will be closed using suture and coating the incision line with a tissue adhesive. No covering stents or packs should be employed. The CTG will be sling sutured in place and the flap secured using a double sling suturing technique.

Soft tissue flap + Geistlich Fibro-Gide®

Device

The treatment site is accessed using a full thickness flap extending at least 1 full tooth mesial and distal, vertical releasing incisions may be used to obtain flap release for full coverage of the treatment site and matrix without compression. Geistlich Fibro-Gide® is cut to shape to the treatment site and placed dry into the site. The flap is secured using a double sling suturing technique.

Primary outcomes

  1. Change in gingival soft tissue volume assessed with 3D scanning

    Time frame: 6 months post treatment

    Change in gingival soft tissue volume compared to baseline [Time Frame 6 months post-treatment] Measured by digital contour scan

Secondary outcomes

  1. All Adverse Events, serious and non serious

    Time frame: Day 0, after 2, 4, 12weeks, 6 Months, 1,3,5 Years

    Recording and Assessment of all (S)AEs starting from Visit 2 onwards, Surgery

  2. Post-OP Patient Reported Outcome Questionnaire

    Time frame: 6 Months, 1,3,5 Years

    subjects will answer a questionnaire regarding discomfort, esthetic satisfaction and overall satisfaction questions asked by a 3rd-party rec

    At Visits 2-weeks, and 1- and 3-months post-operative, subjects will answer discomfort/ pain questions asked by a 3rd-party recorder.

  3. Concomitant medication

    Time frame: 2,4,12 weeks, 6 months, 1,3,5 Years

    Concomitant medication review compared with Visit 1 and 2

  4. Change in gingival soft tissue contour

    Time frame: 3 months, 1,3, 5 Years

    soft tissue contour measured digitally ( 3D-scan) and compared with baseline

  5. General Periodontal Examination (GPE)

    Time frame: 4, 12 weeks, 6 Months, 1,3,5 Years

    Changes of GPE at various visits compared to baseline,

  6. Pink esthetic score (PES)

    Time frame: 6 Months, 1,3,5 Years

    pink esthetic score evaluates soft tissue around single-tooth implants. The PES is based on seven variables: Mesial papilla, Distal papilla, Soft tissue Level, Soft-tissue contour, Alveolar process deficiency, Soft-tissue Color, Soft tissue texture, 2-1-0 score

Sponsors and collaborators

Lead sponsor

Geistlich Pharma AG

Industry

Collaborators

  • Medelis Inc.

Registry information

Official study title

A Prospective, Randomized and Controlled Multi-center Study of Geistlich Fibro-Gide® Compared With Connective Tissue Graft for Soft Tissue Volume Augmentation Around Dental Implants

Important dates

Study start
2018
Primary completion
2021
Study completion
2026
First posted
Jan 11, 2021
Registry last updated
Sep 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.